Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Ping An Healthcare and Technology (Ping An Good Doctor) operates China's largest integrated online healthcare platform with over 400 million registered users, offering teleconsultation, prescription fulfillment, health management services, and insurance product distribution. Backed by Ping An Insurance Group, the company monetizes through B2C medical services, B2B enterprise health solutions for corporate clients, and commission-based insurance product sales, competing in China's rapidly digitizing $1+ trillion healthcare market.
The platform operates a freemium model where basic consultations drive user acquisition while premium services (specialist consultations, chronic disease management programs) generate revenue. The company leverages its 400M+ user base to cross-sell health products with 20-30% gross margins and earns commissions (typically 5-15%) on insurance products sold through the platform. Enterprise contracts provide recurring SaaS-style revenue from corporate wellness programs. Competitive advantages include Ping An Insurance's 600M customer base for user acquisition, proprietary AI-driven triage systems reducing physician costs, and integrated pharmacy fulfillment network enabling 1-hour delivery in tier-1 cities. The recent shift to profitability (1.7% net margin vs historical losses) reflects improved unit economics as consultation volumes scale and marketing efficiency improves.
Monthly active user (MAU) growth and daily consultation volumes - key indicators of platform engagement and network effects
Average revenue per user (ARPU) trends, particularly conversion rates from free to paid services
Regulatory developments in China's internet healthcare sector, including telemedicine reimbursement policies and online prescription drug sales regulations
Profitability trajectory and operating margin expansion as the platform scales
Enterprise client additions and corporate wellness contract values
Chinese government healthcare digitization initiatives and national health insurance integration progress
Chinese regulatory uncertainty around internet healthcare platforms, including potential restrictions on online prescription drug sales, data privacy requirements under Personal Information Protection Law (PIPL), and telemedicine licensing requirements that could limit service offerings or increase compliance costs
National health insurance reimbursement integration challenges - limited coverage for online consultations versus in-person visits reduces addressable market and pricing power
Physician supply constraints in China's healthcare system limiting platform scalability, with quality doctors preferring traditional hospital employment over platform gig work
Intense competition from Alibaba Health, JD Health, and WeChat-integrated telemedicine services, all with comparable user bases and deeper e-commerce integration for product sales
Traditional hospital systems developing proprietary digital platforms, potentially disintermediating third-party platforms as hospitals seek direct patient relationships
Commoditization risk for basic consultation services driving price competition and margin pressure, with differentiation dependent on AI capabilities and specialist network quality
Narrow profitability (1.7% net margin) provides limited buffer against operational disruptions or increased competition requiring defensive marketing spend
Dependence on Ping An Insurance Group for strategic support and user acquisition synergies - any strategic shift by parent could impact growth trajectory
Low free cash flow generation ($0.1B FCF on $3.8B market cap) limits financial flexibility for acquisitions or aggressive expansion without equity dilution
moderate - Healthcare services demonstrate defensive characteristics with inelastic demand for basic medical consultations regardless of economic conditions. However, discretionary health products (supplements, wellness programs) and corporate wellness contracts show cyclical sensitivity. During economic slowdowns, enterprise clients may reduce wellness program budgets and consumers may defer non-urgent specialist consultations. China's GDP growth directly impacts middle-class expansion, which drives adoption of premium digital health services. The company's 3% revenue growth amid China's post-COVID economic normalization suggests some cyclical headwinds.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for unprofitable/low-margin growth companies, particularly impacting the 70x EV/EBITDA multiple; (2) Tighter monetary policy in China reduces consumer discretionary spending on premium health services and supplements. However, the company's zero debt (0.00 D/E ratio) eliminates direct financing cost sensitivity. The primary impact is valuation multiple compression rather than operational pressure.
Minimal direct credit exposure. The company operates on a cash-basis transaction model for consumer services with immediate payment collection. Enterprise contracts typically involve quarterly/annual prepayments. Strong 3.15x current ratio and positive operating cash flow indicate no liquidity concerns. However, indirect credit exposure exists through Ping An Insurance parent company's financial health and willingness to support growth investments.
growth - The 125% YoY stock return reflects momentum investor interest in China's digital health transformation story. Recent profitability inflection attracts growth-at-reasonable-price (GARP) investors seeking exposure to China's healthcare digitization with improving unit economics. However, the -1.9% operating margin and 70x EV/EBITDA multiple indicate this remains a growth story rather than value play. The stock appeals to thematic investors focused on telemedicine adoption, Chinese consumer internet, and healthcare technology convergence.
high - Chinese ADR structure creates inherent volatility from regulatory risk, delisting concerns, and currency fluctuations. The stock's 125% one-year return followed by -4.3% three-month decline demonstrates significant momentum-driven swings. Small-cap healthcare technology stocks in emerging markets typically exhibit 1.5-2.0x beta to broader indices. Regulatory announcements regarding Chinese internet platforms or healthcare policy can trigger 10-20% single-day moves.
